The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile

Preclinical and clinical studies demonstrated that the inhibition of cholinergic supersensitivity through nicotinic antagonists and partial agonists can be used successfully to treat depressed patients, especially those who are poor responders to selective serotonin reuptake inhibitors (SSRIs). In o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Li-Fang, Brek Eaton, J, Zhang, Han-Kun, Sabath, Emily, Hanania, Taleen, Li, Guan-Nan, van Breemen, Richard B, Whiteaker, Paul, Liu, Qiang, Wu, Jie, Chang, Yong-Chang, Lukas, Ronald J, Brunner, Dani, Kozikowski, Alan P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184702/
https://www.ncbi.nlm.nih.gov/pubmed/25505580
http://dx.doi.org/10.1002/prp2.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184702/
https://www.ncbi.nlm.nih.gov/pubmed/25505580
http://dx.doi.org/10.1002/prp2.26

Ejemplares similares